{"protocolSection":{"identificationModule":{"nctId":"NCT00729326","orgStudyIdInfo":{"id":"H8O-US-GWCV"},"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione","officialTitle":"Comparison of the Effect of Exenatide vs. Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione"},"statusModule":{"statusVerifiedDate":"2015-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-08"},"primaryCompletionDateStruct":{"date":"2009-10","type":"ACTUAL"},"completionDateStruct":{"date":"2009-10","type":"ACTUAL"},"studyFirstSubmitDate":"2008-08-04","studyFirstSubmitQcDate":"2008-08-06","studyFirstPostDateStruct":{"date":"2008-08-07","type":"ESTIMATED"},"resultsFirstSubmitDate":"2010-10-12","resultsFirstSubmitQcDate":"2010-12-19","resultsFirstPostDateStruct":{"date":"2011-01-20","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-03-20","lastUpdatePostDateStruct":{"date":"2015-04-09","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"},"collaborators":[{"name":"Eli Lilly and Company","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This study is designed to compare the short-term effects and mechanisms of action of exenatide with those of sitagliptin when either is added to an oral agent(metformin or a thiazolidinedione \\[TZD\\]) in adult patients with type 2 diabetes mellitus(T2DM) with inadequate glycemic control."},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"],"keywords":["diabetes","exenatide","sitagliptin","Amylin","Lilly","metformin","thiazolidinedione"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"CROSSOVER","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":83,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Sequence A","type":"EXPERIMENTAL","interventionNames":["Drug: exenatide","Drug: sitagliptin","Drug: placebo"]},{"label":"Sequence B","type":"EXPERIMENTAL","interventionNames":["Drug: exenatide","Drug: sitagliptin","Drug: placebo"]}],"interventions":[{"type":"DRUG","name":"exenatide","description":"subcutaneous injection (5mcg or 10mcg), twice a day","armGroupLabels":["Sequence A","Sequence B"],"otherNames":["Byetta"]},{"type":"DRUG","name":"sitagliptin","description":"oral administration (100mg), once a day in the morning","armGroupLabels":["Sequence A","Sequence B"],"otherNames":["Januvia"]},{"type":"DRUG","name":"placebo","description":"subcutaneous injection (5mcg or 10mcg), twice a day","armGroupLabels":["Sequence A","Sequence B"]},{"type":"DRUG","name":"placebo","description":"oral administration (100mg), once a day in the morning","armGroupLabels":["Sequence A","Sequence B"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in Time-averaged Glucose During a 24 Hour Period","description":"Change in time-averaged glucose during a 24-hour period from baseline to endpoint (i.e., time-averaged glucose over 24 hours at endpoint minus time-averaged glucose over 24 hours at baseline).","timeFrame":"baseline and 8 Weeks"}],"secondaryOutcomes":[{"measure":"Change in Two-hour Postprandial Glucose After the Morning Meal","description":"Change in 2 hour post-prandial glucose after the morning meal from baseline to endpoint (i.e., glucose level 2 hours after the morning meal at baseline minus glucose level 2 hours after the morning meal at endpoint)","timeFrame":"baseline and 8 Weeks"},{"measure":"Change in Fasting Blood Glucose After the Morning Meal","description":"Change in fasting blood glucose after the morning meal from baseline to endpoint (i.e., fasting blood glucose after the morning meal at baseline minus fasting blood glucose after the morning meal at endpoint)","timeFrame":"baseline and 8 Weeks"},{"measure":"Change in Postprandial Glucagon Area Under the Concentration-time Curve (AUC) After the Morning Meal","description":"Change in Postprandial Glucagon AUC after the morning meal (t=0 to 4 hours) (i.e., Glucagon AUC over the first 4 hours following the morning meal at baseline minus glucagon AUC over the first 4 hours following the morning meal at endpoint)","timeFrame":"baseline and 8 Weeks"},{"measure":"Change in Postprandial Glucagon AUC Excursion After the Morning Meal","description":"Change in postprandial glucagon AUC excursion after the morning meal (t=0 to 4 hours) (i.e., glucagon AUC excursion for 4 hours following the morning meal at baseline minus glucagon AUC excursion for 4 hours following the morning meal at endpoint)","timeFrame":"baseline and 8 Weeks"},{"measure":"Change in Postprandial Triglyceride AUC After the Morning Meal","description":"Change in postprandial triglyceride AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial triglyceride AUC after the morning meal at baseline minus postprandial triglyceride AUC after the morning meal at endpoint)","timeFrame":"baseline and 8 Weeks"},{"measure":"Change in Postprandial Triglyceride AUC Excursion After the Morning Meal","description":"Change in postprandial triglyceride AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial triglyceride AUC excursion after the morning meal at baseline minus postprandial triglyceride AUC excursion after the morning meal at endpoint)","timeFrame":"baseline and 8 Weeks"},{"measure":"Change in Postprandial C-peptide AUC After the Morning Meal","description":"Change in postprandial C-peptide AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial C-peptide AUC after the morning meal at baseline minus postprandial C-peptide AUC after the morning meal at endpoint)","timeFrame":"baseline and 8 Weeks"},{"measure":"Change in Postprandial C-peptide AUC Excursion After the Morning Meal","description":"Change in Postprandial C-peptide AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial C-peptide AUC excursion after the morning meal at baseline minus postprandial C-peptide AUC excursion after the morning meal at endpoint)","timeFrame":"baseline and 8 Weeks"},{"measure":"Change in Postprandial Insulin AUC After the Morning Meal","description":"Change in postprandial insulin AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial insulin AUC after the morning meal at baseline minus postprandial insulin AUC after the morning meal at endpoint)","timeFrame":"baseline and 8 Weeks"},{"measure":"Change in Postprandial Insulin AUC Excursion After the Morning Meal","description":"Change in Postprandial insulin AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial insulin AUC excursion after the morning meal at baseline minus postprandial insulin AUC excursion after the morning meal at endpoint)","timeFrame":"baseline and 8 Weeks"},{"measure":"Change in Postprandial Active GLP-1 AUC After the Morning Meal","description":"Change in Postprandial active GLP-1 AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial active GLP-1 AUC after the morning meal at baseline minus postprandial active GLP-1 AUC after the morning meal at endpoint)","timeFrame":"baseline and 8 Weeks"},{"measure":"Change in Postprandial Active GLP-1 AUC Excursion After the Monrning Meal","description":"Change in Postprandial active GLP-1 AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial active GLP-1 AUC excursion after the morning meal at baseline minus postprandial active GLP-1 AUC excursion after the morning meals at endpoint)","timeFrame":"baseline and 8 Weeks"},{"measure":"Percentage of Patients Experiencing Hypoglycemia (Baseline to Week 4)","description":"Percentage of patients experiencing minor hypoglycemia with a confirmed glucose \\<54mg/dL","timeFrame":"4 Weeks"},{"measure":"Episodes of Hypoglycemia (Baseline to Week 4)","description":"Number of episodes of hypoglycemia experienced during the first 4 weeks of the study","timeFrame":"4 weeks"},{"measure":"Percentage of Patients Experiencing Hypoglycemia (Week 4 to Week 8)","description":"Percentage of patients experiencing minor hypoglycemia with a confirmed glucose \\<54mg/dL","timeFrame":"8 weeks"},{"measure":"Episodes of Hypoglycemia (Week 4 to Week 8)","description":"Number of episodes of hypoglycemia experienced between week 4 and week 8 of the study","timeFrame":"8 weeks"},{"measure":"Percentage of Patients Experiencing Hypoglycemia (Overall)","description":"Percentage of patients experiencing minor hypoglycemia with a confirmed glucose \\<54mg/dL","timeFrame":"4 weeks and 8 weeks"},{"measure":"Episodes of Hypoglycemia (Overall)","description":"Number of episodes of hypoglycemia experienced overall during the study","timeFrame":"4 weeks and 8 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have type 2 diabetes\n* Has HbA1c 7.0% to 11.0%, at or within 4 weeks prior to Visit 1.\n* Have a fasting glucose concentration \\<280 mg/dL at Visit 1\n* Have been treated with a stable dose of immediate or extended release metformin for at least 60 days prior to screening OR TZD (rosiglitazone or pioglitazone) for at least 120 days prior to screening.\n* Are between 18 and 70 years of age, inclusive.\n* Have body mass index ≥25 kg/m2 and ≤45 kg/m2.\n* Have a history of stable body weight (not varying by \\>10% for at least 3 months prior to screening).\n* Can swallow oral study drug capsule, without splitting or crushing.\n\nExclusion Criteria:\n\n* Female patients of childbearing potential (not surgically sterilized and between menarche and 1 year postmenopause) who meet any of the following criteria:\n\n  * Are breastfeeding.\n  * Test positive for pregnancy at the time of screening.\n  * Intend to become pregnant during the study.\n  * Have not practiced a reliable method of birth control (for example, use of oral contraceptives or Norplant®; diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices; partner with vasectomy; or abstinence) for 3 months prior to screening.\n* Treated with any of the following medications:\n\n  * Insulin, exenatide, pramlintide, sulfonylureas or meglitinides within 3 months of screening\n  * Alpha-glucosidase inhibitor within 2 months of screening.\n  * Drugs that directly affect gastrointestinal motility, including, but not limited to metoclopramide, cisapride, and chronic macrolide antibiotics.\n  * Use of a drug for weight loss (for example, prescription drugs such as orlistat, sibutramine, phentermine, or similar over-the-counter medications) within 3 months prior to Visit 1.\n  * Systemic corticosteroids by oral, intravenous, or intramuscular route within 2 months of screening.\n* Have a history of renal transplantation or are currently receiving renal dialysis.\n* Have obvious clinical signs or symptoms of liver disease or acute or chronic hepatitis.\n* Have known active proliferative retinopathy or macular edema expected to need treatment with focal photocoagulation within 3 months.\n* Have an active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.\n* Have had organ transplantation.\n* Have received GLP-1 analogs other than exenatide or DPP-4 inhibitors within the previous 3 months.\n* Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Chief Medical Officer, MD","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Research Site","city":"San Antonio","state":"Texas","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Exenatide Followed By Sitagliptin","description":"Exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks. Followed by exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks."},{"id":"FG001","title":"Sitagliptin Followed By Exenatide","description":"Exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks. Followed by exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"41"},{"groupId":"FG001","numSubjects":"42"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"33"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"9"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Subject Decision","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Sponsor Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Exenatide Followed By Sitagliptin","description":"Exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks. Followed by exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks."},{"id":"BG001","title":"Sitagliptin Followed By Exenatide","description":"Exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks. Followed by exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"83"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"71"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"12"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"54.7","spread":"10.10"},{"groupId":"BG001","value":"53.5","spread":"9.49"},{"groupId":"BG002","value":"54.1","spread":"9.75"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"48"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"35"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Time-averaged Glucose During a 24 Hour Period","description":"Change in time-averaged glucose during a 24-hour period from baseline to endpoint (i.e., time-averaged glucose over 24 hours at endpoint minus time-averaged glucose over 24 hours at baseline).","populationDescription":"The number of patients was determined based on 90% powering of the study. Analyses were based on data from all randomized patients receiving at least one dose of the study drug and completing at least one treatment period. For each patient, the missing data for some time points were imputed by linear interpolation.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"baseline and 8 Weeks","groups":[{"id":"OG000","title":"Exenatide","description":"Exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks."},{"id":"OG001","title":"Sitagliptin","description":"Exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-41.65","spread":"2.55"},{"groupId":"OG001","value":"-29.56","spread":"2.58"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Null hypothesis: The 24-hour average glucose for exenatide was greater than or equal to that for sitagliptin after 4 weeks of treatment. The primary objective was to compare exenatide with sitagliptin on the time-averaged glucose during the 24-hour inpatient periods after 4 weeks of treatment.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.001","pValueComment":"The p-values were not adjusted. The primary measure was change in 24-hour glucose without multiplicity adjustments for other analyses.","statisticalMethod":"ANCOVA","statisticalComment":"Analyses for continuous variables adjusted for treatment, period, sequence, baseline of the continuous variable.Analysis method was Grizzle's model.","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change in Two-hour Postprandial Glucose After the Morning Meal","description":"Change in 2 hour post-prandial glucose after the morning meal from baseline to endpoint (i.e., glucose level 2 hours after the morning meal at baseline minus glucose level 2 hours after the morning meal at endpoint)","populationDescription":"All patients in FAS who have both baseline and endpoint measurement; Last Observation Carried Forward","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"baseline and 8 Weeks","groups":[{"id":"OG000","title":"Exenatide","description":"Exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks."},{"id":"OG001","title":"Sitagliptin","description":"Exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-108.35","spread":"4.36"},{"groupId":"OG001","value":"-44.43","spread":"4.40"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.001","statisticalMethod":"ANCOVA","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change in Fasting Blood Glucose After the Morning Meal","description":"Change in fasting blood glucose after the morning meal from baseline to endpoint (i.e., fasting blood glucose after the morning meal at baseline minus fasting blood glucose after the morning meal at endpoint)","populationDescription":"All patients in FAS who have both baseline and endpoint measurement; Last Observation Carried Forward","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"baseline and 8 Weeks","groups":[{"id":"OG000","title":"Exenatide","description":"Exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks."},{"id":"OG001","title":"Sitagliptin","description":"Exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.93","spread":"2.70"},{"groupId":"OG001","value":"-28.22","spread":"2.71"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":".766","statisticalMethod":"ANCOVA","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change in Postprandial Glucagon Area Under the Concentration-time Curve (AUC) After the Morning Meal","description":"Change in Postprandial Glucagon AUC after the morning meal (t=0 to 4 hours) (i.e., Glucagon AUC over the first 4 hours following the morning meal at baseline minus glucagon AUC over the first 4 hours following the morning meal at endpoint)","populationDescription":"All patients in the FAS who have both baseline and endpoint measurements; Last Observation Carried Forward","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"pmol*hours/L","timeFrame":"baseline and 8 Weeks","groups":[{"id":"OG000","title":"Exenatide","description":"Exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks."},{"id":"OG001","title":"Sitagliptin","description":"Exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.60","spread":"2.91"},{"groupId":"OG001","value":"-16.91","spread":"2.93"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.001","statisticalMethod":"ANCOVA","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change in Postprandial Glucagon AUC Excursion After the Morning Meal","description":"Change in postprandial glucagon AUC excursion after the morning meal (t=0 to 4 hours) (i.e., glucagon AUC excursion for 4 hours following the morning meal at baseline minus glucagon AUC excursion for 4 hours following the morning meal at endpoint)","populationDescription":"All patients in the FAS who have both baseline and endpoint measurements; Last Observation Carried Forward","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"pmol*hours/L","timeFrame":"baseline and 8 Weeks","groups":[{"id":"OG000","title":"Exenatide","description":"Exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks."},{"id":"OG001","title":"Sitagliptin","description":"Exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.94","spread":"2.12"},{"groupId":"OG001","value":"-14.93","spread":"2.13"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.001","statisticalMethod":"ANCOVA","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change in Postprandial Triglyceride AUC After the Morning Meal","description":"Change in postprandial triglyceride AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial triglyceride AUC after the morning meal at baseline minus postprandial triglyceride AUC after the morning meal at endpoint)","populationDescription":"All patients in the FAS who have both baseline and endpoint measurements; Last Observation Carried Forward","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg*hours/dL","timeFrame":"baseline and 8 Weeks","groups":[{"id":"OG000","title":"Exenatide","description":"Exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks."},{"id":"OG001","title":"Sitagliptin","description":"Exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"0.03"},{"groupId":"OG001","value":"0.87","spread":"0.03"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":".117","statisticalMethod":"ANCOVA","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change in Postprandial Triglyceride AUC Excursion After the Morning Meal","description":"Change in postprandial triglyceride AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial triglyceride AUC excursion after the morning meal at baseline minus postprandial triglyceride AUC excursion after the morning meal at endpoint)","populationDescription":"All patients in the FAS who have both baseline and endpoint measurements; Last Observation Carried Forward","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg*hours/dL","timeFrame":"baseline and 8 Weeks","groups":[{"id":"OG000","title":"Exenatide","description":"Exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks."},{"id":"OG001","title":"Sitagliptin","description":"Exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-108.16","spread":"8.38"},{"groupId":"OG001","value":"-41.39","spread":"8.45"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.001","statisticalMethod":"ANCOVA","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change in Postprandial C-peptide AUC After the Morning Meal","description":"Change in postprandial C-peptide AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial C-peptide AUC after the morning meal at baseline minus postprandial C-peptide AUC after the morning meal at endpoint)","populationDescription":"All patients in the FAS who have both baseline and endpoint measurements; Last Observation Carried Forward","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"nmol*hours/L","timeFrame":"baseline and 8 Weeks","groups":[{"id":"OG000","title":"Exenatide","description":"Exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks."},{"id":"OG001","title":"Sitagliptin","description":"Exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.78","spread":"0.28"},{"groupId":"OG001","value":"0.25","spread":"0.28"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.001","statisticalMethod":"ANCOVA","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change in Postprandial C-peptide AUC Excursion After the Morning Meal","description":"Change in Postprandial C-peptide AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial C-peptide AUC excursion after the morning meal at baseline minus postprandial C-peptide AUC excursion after the morning meal at endpoint)","populationDescription":"All patients in the FAS who have both baseline and endpoint measurements; Last Observation Carried Forward","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"nmol*hours/L","timeFrame":"baseline and 8 Weeks","groups":[{"id":"OG000","title":"Exenatide","description":"Exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks."},{"id":"OG001","title":"Sitagliptin","description":"Exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.83","spread":"0.29"},{"groupId":"OG001","value":"0.14","spread":"0.29"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.001","statisticalMethod":"ANCOVA","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change in Postprandial Insulin AUC After the Morning Meal","description":"Change in postprandial insulin AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial insulin AUC after the morning meal at baseline minus postprandial insulin AUC after the morning meal at endpoint)","populationDescription":"All patients in the FAS who have both baseline and endpoint measurements; Last Observation Carried Forward","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"pmol*hours/L","timeFrame":"baseline and 8 Weeks","groups":[{"id":"OG000","title":"Exenatide","description":"Exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks."},{"id":"OG001","title":"Sitagliptin","description":"Exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-396.12","spread":"56.79"},{"groupId":"OG001","value":"-8.79","spread":"57.32"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.001","statisticalMethod":"ANCOVA","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change in Postprandial Insulin AUC Excursion After the Morning Meal","description":"Change in Postprandial insulin AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial insulin AUC excursion after the morning meal at baseline minus postprandial insulin AUC excursion after the morning meal at endpoint)","populationDescription":"All patients in the FAS who have both baseline and endpoint measurements; Last Observation Carried Forward","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"pmol*hours/L","timeFrame":"baseline and 8 Weeks","groups":[{"id":"OG000","title":"Exenatide","description":"Exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks."},{"id":"OG001","title":"Sitagliptin","description":"Exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-525.01","spread":"58.77"},{"groupId":"OG001","value":"-34.83","spread":"59.40"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.001","statisticalMethod":"ANCOVA","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change in Postprandial Active GLP-1 AUC After the Morning Meal","description":"Change in Postprandial active GLP-1 AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial active GLP-1 AUC after the morning meal at baseline minus postprandial active GLP-1 AUC after the morning meal at endpoint)","populationDescription":"All patients in the FAS who have both baseline and endpoint measurements; Last Observation Carried Forward","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"pmol*hours/L","timeFrame":"baseline and 8 Weeks","groups":[{"id":"OG000","title":"Exenatide","description":"Exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks."},{"id":"OG001","title":"Sitagliptin","description":"Exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.28","spread":"3.12"},{"groupId":"OG001","value":"47.37","spread":"3.15"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.001","statisticalMethod":"ANCOVA","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change in Postprandial Active GLP-1 AUC Excursion After the Monrning Meal","description":"Change in Postprandial active GLP-1 AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial active GLP-1 AUC excursion after the morning meal at baseline minus postprandial active GLP-1 AUC excursion after the morning meals at endpoint)","populationDescription":"All patients in the FAS who have both baseline and endpoint measurements; Last Observation Carried Forward","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"pmol*hours/L","timeFrame":"baseline and 8 Weeks","groups":[{"id":"OG000","title":"Exenatide","description":"Exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks."},{"id":"OG001","title":"Sitagliptin","description":"Exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.04","spread":"3.28"},{"groupId":"OG001","value":"23.53","spread":"3.31"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.001","statisticalMethod":"ANCOVA","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Percentage of Patients Experiencing Hypoglycemia (Baseline to Week 4)","description":"Percentage of patients experiencing minor hypoglycemia with a confirmed glucose \\<54mg/dL","populationDescription":"All patients in FAS","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of patients","timeFrame":"4 Weeks","groups":[{"id":"OG000","title":"Exenatide","description":"Exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks."},{"id":"OG001","title":"Sitagliptin","description":"Exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"37"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9"},{"groupId":"OG001","value":"2.7"}]}]}]},{"type":"SECONDARY","title":"Episodes of Hypoglycemia (Baseline to Week 4)","description":"Number of episodes of hypoglycemia experienced during the first 4 weeks of the study","populationDescription":"Full analysis set","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"episodes of hypoglycemia","timeFrame":"4 weeks","groups":[{"id":"OG000","title":"Exenatide","description":"Exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks."},{"id":"OG001","title":"Sitagliptin","description":"Exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"37"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Experiencing Hypoglycemia (Week 4 to Week 8)","description":"Percentage of patients experiencing minor hypoglycemia with a confirmed glucose \\<54mg/dL","populationDescription":"All patients in FAS","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of patients","timeFrame":"8 weeks","groups":[{"id":"OG000","title":"Exenatide","description":"Exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks."},{"id":"OG001","title":"Sitagliptin","description":"Exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"34"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7"},{"groupId":"OG001","value":"0.0"}]}]}]},{"type":"SECONDARY","title":"Episodes of Hypoglycemia (Week 4 to Week 8)","description":"Number of episodes of hypoglycemia experienced between week 4 and week 8 of the study","populationDescription":"All patients in FAS","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"episodes of hypoglycemia","timeFrame":"8 weeks","groups":[{"id":"OG000","title":"Exenatide","description":"Exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks."},{"id":"OG001","title":"Sitagliptin","description":"Exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"34"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Experiencing Hypoglycemia (Overall)","description":"Percentage of patients experiencing minor hypoglycemia with a confirmed glucose \\<54mg/dL","populationDescription":"All patients in FAS","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of patients","timeFrame":"4 weeks and 8 weeks","groups":[{"id":"OG000","title":"Exenatide","description":"Exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks."},{"id":"OG001","title":"Sitagliptin","description":"Exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"71"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3"},{"groupId":"OG001","value":"1.4"}]}]}]},{"type":"SECONDARY","title":"Episodes of Hypoglycemia (Overall)","description":"Number of episodes of hypoglycemia experienced overall during the study","populationDescription":"All patients in FAS","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"episodes of hypoglycemia","timeFrame":"4 weeks and 8 weeks","groups":[{"id":"OG000","title":"Exenatide","description":"Exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks."},{"id":"OG001","title":"Sitagliptin","description":"Exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"71"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Exenatide","description":"Exenatide 5mcg plus sitagliptin placebo for 1 week, then exenatide 10mcg plus sitagliptin placebo for 3 weeks.","seriousNumAffected":2,"seriousNumAtRisk":73,"otherNumAffected":43,"otherNumAtRisk":73},{"id":"EG001","title":"Sitagliptin","description":"Exenatide placebo plus sitagliptin 100mg for 1 week, then exenatide placebo plus sitagliptin 100mg for 3 weeks.","seriousNumAffected":0,"seriousNumAtRisk":73,"otherNumAffected":37,"otherNumAtRisk":73}],"seriousEvents":[{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":73}]},{"term":"Angioedema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":73}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":73}]}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":73},{"groupId":"EG001","numAffected":12,"numAtRisk":73}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":73},{"groupId":"EG001","numAffected":4,"numAtRisk":73}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":73},{"groupId":"EG001","numAffected":9,"numAtRisk":73}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":73},{"groupId":"EG001","numAffected":8,"numAtRisk":73}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":73},{"groupId":"EG001","numAffected":5,"numAtRisk":73}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":73},{"groupId":"EG001","numAffected":5,"numAtRisk":73}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":73},{"groupId":"EG001","numAffected":3,"numAtRisk":73}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":73}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":73},{"groupId":"EG001","numAffected":5,"numAtRisk":73}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":73}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":73},{"groupId":"EG001","numAffected":2,"numAtRisk":73}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":73},{"groupId":"EG001","numAffected":5,"numAtRisk":73}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":73},{"groupId":"EG001","numAffected":5,"numAtRisk":73}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Peter Ohman, Medical Science Director","organization":"AstraZeneca","email":"ClinicalTrialTransparency@astrazeneca.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D003924","term":"Diabetes Mellitus, Type 2"},{"id":"D003920","term":"Diabetes Mellitus"}],"ancestors":[{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077270","term":"Exenatide"},{"id":"D000068900","term":"Sitagliptin Phosphate"}],"ancestors":[{"id":"D010455","term":"Peptides"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D014688","term":"Venoms"},{"id":"D045424","term":"Complex Mixtures"},{"id":"D014118","term":"Toxins, Biological"},{"id":"D001685","term":"Biological Factors"},{"id":"D014230","term":"Triazoles"},{"id":"D001393","term":"Azoles"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D011719","term":"Pyrazines"}]}},"hasResults":true}